Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on November 26, 2018, 10:16:44 am
-
People who switch from the old version of the antiretroviral (ARV) tenofovir to the new iteration may be inclined to gain weight.
The Food and Drug Administration (FDA) recently approved a slate of new combination tablets from Gilead Sciences in which the pharmaceutical company replaced the drug tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide fumarate (TAF). As a standalone pill, TAF, known by the brand name Vemlidy, is also approved for the treatment of hepatitis B virus (HBV).
Read more...
https://www.hepmag.com/article/switching-new-version-antiretroviral-tenofovir-may-lead-weight-gain